Here you will find all our clinical education resources from articles to recorded webinars, all supporting equitable access to funded medicines.
This podcast demonstrates how the three-step Ask, Build, Check health literacy model can be incorporated into discussions about the long-term management of gout, to help improve patient outcomes.
Please note that this is the podcast version of the video Let's talk gout.
Prescribers are instrumental in framing a medicine positively or negatively, setting patient expectations. Optimising these expectations during a short consult can enhance and sustain benefits. Conversely, highlighting negative information may lead to increased experience, and reporting, of adverse events, and to poor adherence.
Episode three of our Legendary Conversations podcast is out now! Listen to three experts as they discuss attitudes towards gout and how to better communicate with patients to improve gout outcomes.
Rosuvastatin is now fully funded on Special Authority for people at increased risk of cardiovascular complications due to high cholesterol, and may be considered first-line for Māori and Pacific peoples.
An abridged version of this article, containing the eligibility flowchart, is available for printing - see the link in the contents box.
Episode two of our Legendary Conversations podcast is out now! Listen to a scripted discussion that uses the Ask, Build, Check health literacy model when talking with a patient about starting a new medicine.
The jury is in – usual gout care isn’t working well, especially for Māori and Pacific peoples, who are disproportionately affected by this common disorder.
What potential tools are readily available to reduce gout harm? Specific clinician actions!
Read the bulletin to find out more.
Looking for up-to-date information on gout? You can find it here!
We’ve linked resources from multiple providers into one place so it’s easy for you to find what you need.
Following on from presentations in February, this new resource covers discussions from webinars held in August 2021.
The content has been edited, and reviewed by Waikato DHB endocrinologist/diabetologist Dr Ryan Paul.
We recommend using Google Chrome when accessing this resource. You may experience technical difficulties on other internet browsers.
Introducing Legendary Conversations, our podcast series that explores aspects of primary care in Aotearoa New Zealand. In episode one (part 1), we talk with Professor Keith Petrie about the psychological effects of taking medicines, and what primary healthcare professionals need to know.
Linda Bryant discusses gout, a chronic long-term condition that is often associated with other diseases, and with drug-related morbidity and mortality. As such, it needs to be addressed holistically as part of the psychosocial medical model.
Biological medicines have markedly changed prognoses for many conditions such as cancers, diabetes and autoimmune diseases.
As biologics’ patents expire, biosimilars – highly similar versions of approved biologic brands – will be competitively marketed. This will lead to cost savings, increased access and treatment options, and improved patient outcomes.
Read the HAH Bulletin to find out more.
Since originally publishing this article in September 2021, selegiline has been discontinued and supplies have been depleted. Rasagiline is now the only funded MAO-B inhibitor available in New Zealand.
This resource provides advice on prescribing and supplying rasagiline, which is currently funded but not yet approved by Medsafe.